



### SUPPLEMENTAL APPLICATION

# UNDERWRITTEN BY: THE HANOVER INSURANCE COMPANY

### **CLAIMS MADE NOTICE**

THIS POLICY PROVIDES COVERAGE ON A CLAIMS-MADE BASIS. SUBJECT TO ITS TERMS, THIS POLICY APPLIES ONLY TO "CLAIMS" FIRST MADE AGAINST "YOU" DURING THE "POLICY PERIOD", AUTOMATIC EXTENDED REPORTING PERIOD OR ANY PURCHASED OPTIONAL EXTENDED REPORTING PERIOD THAT MAY APPLY. PLEASE READ THE POLICY CAREFULLY TO DETERMINE RIGHTS, DUTIES, COVERAGE AND COVERAGE RESTRICTIONS.

#### "CLAIM EXPENSE" WITHIN LIMITS

THIS CLAIMS-MADE POLICY PROVIDES FOR "CLAIM EXPENSE" PAYABLE WITHIN, AND NOT IN ADDITION TO, THE LIMITS OF INSURANCE. "CLAIM EXPENSE" WILL REDUCE AND MAY EXHAUST THE LIMIT OF INSURANCE AND WILL BE APPLIED AGAINST THEDEDUCTIBLE. PLEASE READ THE POLICY CAREFULLY TO DETERMINE RIGHTS, DUTIES, COVERAGE AND COVERAGE RESTRICTIONS.

#### **APPLICATION INSTRUCTIONS**

Please answer all required sections of questions completely. The following sections are required for all applicants: General Information, Products-Completed Operations Liability, and Products-Completed Operations—Regulatory and Risk Management. Select the additional coverage options you would like to apply for by completing all the required questions for each coverage.

Whenever used in this Application, the term you or your(s) or the Applicant shall mean the Named Insured and all subsidiaries, unless otherwise stated.

#### I. GENERAL INFORMATION

#### A. YOUR BUSINESS OPERATIONS

1.	Name of Applicant:	
2.	Address of Applicant:	
	Website Address:	
	Years in Business?	
5.	Have you ever operated under another name?	□Yes □No
	If Yes, please explain:	
6.	Do you have a parent company?	□Yes □No
	If Yes, provide name:	
7.	Please list all your subsidiaries and your percentage of ownership in each:	
8.	In the past 5 years, have you engaged in any mergers, acquisitions, or divestitures?	☐Yes ☐No
	If Yes, please provide the date and whether you acquired, retained or divested assets, liabilities or both for each transaction:	

Page 1 of 22

	9.	For	each merger or acquisitio	n, did you do yo	our due diligenc	e process inclu	ude the followir	ng:	
			Review of prior and pendi		3	•		□Yes	□No
			If Yes, please provide a b	-	<u>.</u>				
		b.		-				f	
<ul> <li>Evaluation of all outstanding contracts or service agreements to be included as part the transaction?</li> </ul>									□No
		C.	Analysis of intellectual prothese rights?	perty rights, in	cluding any third	d party interest	in or liens on	□Yes	□No
	10	Цал	e you filed for bankruptcy	in the past 7 w	nare?			□Yes	_
						0			
			you in compliance with all	-		es?		∐Yes	∐No
	12.	Ple	ase list any industry trade	association me	mberships:				
В.	ΑP	PLIC	CANT INSURANCE INFO	RMATION					
Ple	ase	prov	ride information on your cu	rrent insurance	e program:				
	licy riod		Insurance Company	Coverage	Limits	Deductible	Retroactive Date	Pren	nium
					\$	\$		\$	
					\$	\$		\$	
					\$	\$		\$	
					\$	\$		\$	
	1.		our current Products-Com ims-Made basis?	pleted Operation	ons Liability cove	erage form pro	vided on a	∐Yes	□No
	2.	Hav	ve you discontinued or cea	sed to provide	any products, se	ervices or ope	rations in the		
			five years?	·		•		□Yes	□No
		a.	If Yes, please provide det	ails:					
		b.	And if Yes, do you provide products, services or ope	_	rvices, support of	or other remed	ies for disconti	nued Yes	□No
			If Yes, please provide det					□163	Шио
	•	Б.	•	·			1		
	3.		es your current insurance polices?	orogram exclud	le any of your cli	inical trials, pro	oducts or	∐Yes	□No
		If Y	es, please provide details:						
C.	RE	QUE	STED INSURANCE PRO	GRAM					
Ple	ase	prov	ride information on your re	quested insura	nce program:				
_					1 3				

COVERAGE	Limits	Deductible	Retroactive Date(s)
Products-Completed Operations Liability	\$	\$	
Errors & Omissions	\$	\$	
Information Security	\$	\$	
Privacy and Personal Injury	\$	\$	
Media and Content	\$	\$	
Data Breach Expense	\$	\$	
Products Recall Expense	\$	\$	
Human Clinical Trial Expense	\$		

1.	Please provide a description of your busin	ness operations:			
2.	Describe any new products or services end use than your current products or services.		e substantially differe	nt in scop	e or
3.	Do you anticipate any significant changes 12 months?  If Yes, please provide details:	s in the nature of your bu	siness over the next	□Yes	□No
4.	Please provide a breakdown of your reve	nue:			
	SOURCES OF REVENUE  otal U.S. Revenue  otal Foreign Revenue	Current Annual Revenues	Projected Annual Revenues		
	otal Revenue				
5.	Please provide a breakdown of your prod	lucts or services by perce	entage of your total rev	/enue:	
	SOURCES OF REVEN		Projected Annua Revenues		
Pł	narmaceuticals / Biologics			%	
	etary Supplement			%	
	edical Devices			%	
	gital Health ontract Research Organization and/or Res	earch Institute		% %	
	her:	caron manaic		%	
	•		1-0		N.
6.	Do you have any association, past or pre	sent, with banned produc	CIS?	∐Yes	∐No
_	If Yes, please provide details:				
7.	Have any of your products, services or or by any U.S. or foreign government agence	=	t to an investigation	□Yes	Пис
	If Yes, please provide details:	•		□163	
8.	Do you utilize nanotechnology in the deve				
0.	products?	elopment, delivery of mai	idiacturing or your	□Yes	□No
	If Yes, please provide details:				
9.	Are your products and services HIPAA co	ompliant?		∐Yes	□No
	a. If No, please provide details:				
	b. Are any products discontinued for sai	fety reasons?		∐Yes	□No
10.	Do you import any products or ingredient	s?		∐Yes	□No
	If Yes, what products/ingredients and what			•	-

		Addictive Substance/Opioids		Radiation Emitting Technologies		
		Birth Control or Fertility		SSRIs or SNRIs		
		Gene Therapy Known		Steroids		
		Hormone Replacement Products		Vaccines		
		HPAPIs or HPAIs		Weight Management		
		Cannabis		Generic Pharmaceuticals		
		Known Carcinogen		Mesh		
		Known Mutagen		Knee Replacement and components		
		Teratogen		Hip Replacement and components		
		Mercury		Shoulder replacement and componen	ts	
		Pediatric/Minors/Pregnant Women		Generative Artificial Intelligence		
		Metal on metal implants				
HIS	STOR	Υ				
1.	With	in the past 5 years:				
		Have you received any allegation(s), claims	s or su	uits (insured or not) claiming		
		defect of any kind and/or damages associa		,	n	
		clinical trials?			□Yes	$\square$ N
	b. I	Have you given notice of any claim, circum	stance	e or potential claim to any insurer		
	1	under any insurance coverage referred to a	bove'	?	□Yes	$\square$ N
	C.	Are you aware of any facts or circumstance	s ass	ociated with your products or		
	;	services that could reasonably be expected	l to re	sult in a claim or suit?	□Yes	$\square$ N
				haita haan waad in any tyna af		
		Have you experienced or has your system				
	;	security incident or attack (e.g. viruses, der			∐Yes	□N
2.	;				□Yes	□N
2.	With a.	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no	nial of	service attacks, etc.)?		
2.	With a.	security incident or attack (e.g. viruses, der in the past 3 years:	nial of	service attacks, etc.)?	□Yes	
2.	With a.	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no	nial of n-per	service attacks, etc.)?		□N
2.	With a.	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no services?	nial of on-per e to co	service attacks, etc.)?  formance of your products or  ontract dispute?	∐Yes	□N
2.	With a.   b.   c.	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no services? Have your customers withheld payment du	nial of n-per e to co on-pa	service attacks, etc.)?  formance of your products or  ontract dispute?  syment?	□Yes □Yes	□x □x
	b.   d.	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no services? Have your customers withheld payment due Have you sued any of your customers for n Have you discovered or been accused of a	nial of n-per e to co on-pa ny typ	service attacks, etc.)?  formance of your products or  ontract dispute?  lyment?  le of privacy violation?	□Yes □Yes □Yes □Yes	□ N □ N
2.	With a.   b.   c.   d.   With	security incident or attack (e.g. viruses, der in the past 3 years: Have you had contract disputes alleging no services? Have your customers withheld payment du Have you sued any of your customers for n	nial of n-per e to co on-pa ny typ cy can	service attacks, etc.)?  formance of your products or  ontract dispute?  lyment? le of privacy violation?  celed or non-renewed?	□Yes □Yes □Yes □Yes □Yes	N   N

### II. PRODUCTS COMPLETED OPERATIONS LIABILITY

### A. PHARMACEUTICALS/BIOLOGICS

(Please complete this section if you manufacture or distribute a pharmaceutical. If you do not, please skip this section.)

1. Please provide a breakdown of your product revenue by product type and number of units sold:

ROUTE OF ADMINISTRATION	Prescription	Generic	Over The Counter	Percentage of Revenue Sold	Number of Units Sold
Topical				%	
Oral				%	
Inhalable				%	
Injectable				%	
Transdermal				%	
Drug Delivery	_			%	
Other				%	

2.	Please provide an overview	of you	ur products and intended uses:		
3.	Do you manufacture a biolog	jic the	erapeutic?		Yes □No
	If Yes, please provide details				
4.	Do you manufacture an Activ	/e Ph	armaceutical Ingredient (API) for:	☐ Y	ourself   Others ?
	If Yes, please provide details	s:			_
5.	Do you have any past, prese Food and Drug Administration		planned products that do not have DA) approval for marketing?	form	al ∐Yes ∐No
	If Yes, what limits of liability:				
6.	Please check the box where any of the following specific	-	nave studies, products, or services naceutical products:	(pas	t, present or future) involving
Acc	cutane		Fenfluramine		Pioglitazone
Ace	etaminophen		Gadolinium		Proton Pump Inhibitors
Ana	abolic steroids		Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD)		Pseudoephedrine
And	drostenedione		Hormone Replacement Products		Redux
Aris	stochochic acid		Isotretinoin		Rosiglitazone
Ber	nzodiazepines		Kratom		Selective Serotonin Reuptake Inhibitors (SSRI)
Birt	h control products		Mercury		Statins
Bis	macine		Metoclopramide		Talc
Bis	phosphonate		Opioids		Testosterone
Car	nnabis		Phenibut		Thalidomide
Cis	apride		Phentermine		Thimerosal
Cox	x-2-inhibitors		Phenylpropanolamine (PPA)		Troglitazone
Di-(	(2-ethylhexyl) Phthalate (DEHP)		Phospho soda, sodium phosphate, or any phosphor soda or sodium phosphate based agents		Usnea and usnic acid

	Die	ethylstilbestrol (DES)										
В.	DIE	ETARY SUPPLEMENTS					_					
		you manufacture or distribute pplements for yourself or other		meceuticals, nutraceuticals, vitamir	s or	food						
	su		□Yes □No									
	If Yes, please answer the remaining questions in this section:  a. Please describe the nature of your products:											
	a.											
	b.	Do any of your products make	e he	alth or lifestyle claims/benefits?			□Yes □No					
		If Yes, please provide details:										
	c. Have any of your products ever fit the definition of a new dietary ingredient?  If Yes, have pre market safety reviews been conducted per regulations?											
	d.	Have any of your products evas a drug by a regulatory age	-	had an active ingredient that would ?	be d	lefined.	□Yes □No					
		If Yes, please provide details	s:									
	e. Do you sell any muscle building, weight management, Cannabis/CBD, energy drinks or sexual enhancement products?											
	If Yes, please provide details:											
	f.	□Yes □No										
	g.	Are you compliant with the m manufacturing and adverse e					□Yes □No					
	J	manufacturing and adverse e	event you		(pas		□Yes □No					
	h.	manufacturing and adverse e	event you	t reporting? have studies, products, or services	(pas		□Yes □No					
	h.	manufacturing and adverse of Please check the box where future) involving any of the fo	you you ollowi	t reporting? have studies, products, or services ing specific dietary supplements:		t, present or	□Yes □No					
	h.	manufacturing and adverse of Please check the box where future) involving any of the for B Dimethyl amylamine (DMAA)	you you ollowi	t reporting? have studies, products, or services ing specific dietary supplements:  Colloidal silver	". 	t, present or Kratom	□Yes □No					
	h. 1,3 1,3 1,4	manufacturing and adverse of Please check the box where future) involving any of the form and Dimethyl amylamine (DMAA). B Dimethyl butylamine (DMBA)	you bllowi	t reporting? have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)		t, present or  Kratom Lobelia	□Yes □No					
	h.  1,3 1,4 An	manufacturing and adverse of Please check the box where future) involving any of the form	you billowi	t reporting? have studies, products, or servicesing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine		Kratom Lobelia Magnolia Phenibut Piper Methysti	cum (Kava)					
	h.  1,3 1,4 An	manufacturing and adverse of Please check the box where future) involving any of the form of the following and please check the box where future) involving any of the form of	you   bllowi	t reporting? have studies, products, or servicesing specific dietary supplements:  Colloidal silver Di-(2-ethylhexyl) Phthalate (DEHP) Ephedra Ephedrine		Kratom Lobelia Magnolia Phenibut	cum (Kava)					
	h.  1,3 1,4 An Ari	manufacturing and adverse of Please check the box where future) involving any of the form	you billowi	have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine  Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4		Kratom Lobelia Magnolia Phenibut Piper Methysti	cum (Kava)					
	h.  1,3 1,3 1,4 An An Ari	manufacturing and adverse of Please check the box where future) involving any of the form in a Dimethyl amylamine (DMAA) is Dimethyl butylamine (DMBA) is Dimethyl pentylamine (DMHA) is abolic steroids indrostenedione istochochic acid	you billowi	have studies, products, or servicesing specific dietary supplements:  Colloidal silver Di-(2-ethylhexyl) Phthalate (DEHP) Ephedra Ephedrine Fenfluramine Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD)		Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I	cum (Kava) nhibitors					
	h.  1,3 1,3 1,4 An An An Ari	manufacturing and adverse of Please check the box where future) involving any of the form	you billowi	have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine  Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4  Butanediol (BD)  Germander		Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I	cum (Kava) nhibitors					
	h.  1,3 1,3 1,4 An Ari  Bitt β-N Ch	manufacturing and adverse of Please check the box where future) involving any of the form	you billowi	have studies, products, or servicesing specific dietary supplements:  Colloidal silver Di-(2-ethylhexyl) Phthalate (DEHP) Ephedra Ephedrine Fenfluramine Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD) Germander Hormone Replacement Products		Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I Testosterone Usnea and usi	cum (Kava) nhibitors					
	h.  1,3 1,4 An An Ari  Bitt β-N Ch	manufacturing and adverse of Please check the box where future) involving any of the form	you no media	have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine  Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD)  Germander  Hormone Replacement Products  Jin Bu huan		Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I Testosterone Usnea and usi Yohimbe	cum (Kava) nhibitors					
	h.  1,3 1,4 An An Ari  Bitt β-N Ch	manufacturing and adverse of Please check the box where future) involving any of the form of the following any of the form of	you not medicate,	have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine  Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD)  Germander  Hormone Replacement Products  Jin Bu huan	r prov	Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I  Testosterone Usnea and usi Yohimbe	cum (Kava) nhibitors					
	h.  1,3 1,3 1,4 An. Ani Ari  Bitt	manufacturing and adverse of Please check the box where future) involving any of the form of the following and of the following any of the following and of the followin	you medianot, elf?	have studies, products, or services ing specific dietary supplements:  Colloidal silver  Di-(2-ethylhexyl) Phthalate (DEHP)  Ephedra  Ephedrine  Fenfluramine  Gamma-hydroxybutyrate (GHB), Gamma Butyrate (GBL), 1,4 Butanediol (BD)  Germander  Hormone Replacement Products  Jin Bu huan  manufacture, assemble, distribute of cal devices, biotechnology products please skip this section.)	r provision la	Kratom Lobelia Magnolia Phenibut Piper Methysti Proton Pump I  Testosterone Usnea and usi Yohimbe  vide service to aboratory at apply:	cum (Kava) nhibitors nic acid  components					

2. Please provide a breakdown of your revenue-by-revenue source:

SOURCE OF REVENUE	For Yourself	For Others	Percentage of Total Revenue
Component manufacturer of a product	%	%	%
Contract manufacturer of a product	%	%	%
Manufacturer of a product	%	%	%
Distributor of a product	%	%	%
Installer, service or repairer of a product	%	%	%
Refurbisher of a product	%	%	%
Other:	%	%	%

	Are your products labeled research use only?									
If you are a component or a contract manufacturer:										
a. Describe the Finished Good product:										
Do you provide design, engin	eering ar	nd prototype services?		∐Yes	□N					
If Yes, please provide details:										
. What percentage of your work is completed to customer specifications?										
-	tomer for any	∐Yes	□N							
If Yes, please provide details:	:									
Are you aware of any product or work?	t recalls b	by your customers that resulted from	om your produ		□No					
If Yes, please provide details:	:									
	•	ve any past, present or planned ir	nvolvement							
Aerospace or aircraft		Implantable medical device								
Automotive		Industrial automation								
Biologics		Latex								
Defense or military		Life sustaining or life supporting medical device								
Drug delivery system		Physical security devices								
	Do you provide design, engine of Yes, please provide details: What percentage of your work Do you have a formal process specification, material or manual of Yes, please provide details: Are you aware of any product or work?  If Yes, please provide details: Pease check the box below when sociated with any of the following Aerospace or aircraft Automotive Biologics  Defense or military  Drug delivery system	Do you provide design, engineering ar If Yes, please provide details:  What percentage of your work is composed provide details:  Do you have a formal process for appropriate pecification, material or manufacturing If Yes, please provide details:  Are you aware of any product recalls be or work?  If Yes, please provide details:  Pease check the box below where you has sociated with any of the following:  Aerospace or aircraft  Automotive  Biologics  Defense or military	Do you provide design, engineering and prototype services?  If Yes, please provide details:  What percentage of your work is completed to customer specifications?  Do you have a formal process for approval and acceptance by your cust specification, material or manufacturing process modifications?  If Yes, please provide details:  Are you aware of any product recalls by your customers that resulted froor work?  If Yes, please provide details:  ease check the box below where you have any past, present or planned in sociated with any of the following:  Aerospace or aircraft  Implantable medical device  Industrial automation  Biologics  Latex  Defense or military  Drug delivery system  Physical security devices	Do you provide design, engineering and prototype services?  If Yes, please provide details:  What percentage of your work is completed to customer specifications?  Do you have a formal process for approval and acceptance by your customer for any specification, material or manufacturing process modifications?  If Yes, please provide details:  Are you aware of any product recalls by your customers that resulted from your product rowork?  If Yes, please provide details:  Passe check the box below where you have any past, present or planned involvement sociated with any of the following:  Aerospace or aircraft  Implantable medical device  Automotive  Industrial automation  Biologics  Latex  Life sustaining or life supporting medical device	Do you provide design, engineering and prototype services?    Yes   If Yes, please provide details:					

### D. DIGITAL HEALTH

(Please complete this section if you provide digital products. If you do not, please skip this section.)

1. Please check all the activities below that apply to your company and the end use environment(s) for your products:

		F	PRODUCT EN	ND USE ENVIF	RONMENT	NMENT(S)				
	PRODUCTS	Clinical	Pharmacy	Laboratory	Home	Mobile				
Electronic, He Health Recor	ealth, Electronic Medical or Personal									
E-Prescription	ns									
Clinical Decis	sion Support									
Computerized	d Physician Ordering Entry									
Drug to Drug	Interactions									
Health Kiosk										
HIPAA Comp	oliance Software/Advisory/Services									
Medication C	oding or Dispensing									
,	lth or Nutritional sory/Services									
Patient Archiv	ving Capturing System									
Patient or Clin	nical Communication Portal									
Patient Mana	gement Software									
Remote Medi	ical Education for Clinicians									
Remote Patie	ent Monitoring									
Unregulated l	FDA Mobile Applications									
Other:										
If 3. D u	Oo you provide standard or customizable fewer of Yes, please provide details:  Oo you perform any functions, activities use or disclosure of protected health into fewer of the fewer of th	or provide		or service that	involves th	  ne Yes □No				
	Oo you provide any hosting, archiving o	or cloud se	rvices of vour	customers' da	ta?	☐Yes ☐No				
	Yes, please provide details:		, , ,							
	How do your products interface with oth		nealth product	s or medical s	ervices?					
is	f you develop or publish Electronic Heas s your software certified by the Office of echnology?					are, □Yes □No				
	Oo you manufacture or distribute any mo compliment your product solution(s)		` .	ents and/or fin	ished good	ls) □Yes □No				
If	Yes, please provide details:									

	8.	Are any of your product device?	s (past, pres	sent or pla	anned) considered a FDA regulate	ed medical [	∐Yes ∐No				
		If Yes, please provide d	etails:								
E.	СО	NTRACT RESEARCH									
	(Please complete this section if you operated as a clinical or contract research organization a research institute. If you do not, please skip this section.)										
	1.	How would you define y	ourself? Ple	ease chec	k the box(es) that apply:						
		☐ Pre-Clinical Con	tract Resea	rch Orgar	nization						
		☐ Clinical Researc	h Organizat	ion							
		Research Institu	te								
	2.	Please check all the act			ly to your company:						
	ا	PRE-CLINICAL	For Yourself	For Others	CLINICAL	For Yourself	For Others				
Bench	Res	earch			Protocol and/or consent form development						
		chemistry including target and validation			Clinical trial management and/or data collection						
		ization and validation			Regulatory support and/or statistica analysis						
In vitro	scre	eening			Pharmacovigilance						
Animal	stud	dies			Medical or pathology services performed onsite						
Toxicol	logy	and/or pathology			Licensing of technology, intellectual property or data to others						
Other:					Providing clinical instructions to others						
Other:					Other:						
	3.	Do you act as a sponso	r or investig	ator for a	ny clinical trials?	[	_Yes				
		If Yes, please explain:	_								
	4.	Do you support the deve	elopment ar	nd/or com	mercialization of any products?	[	_Yes				
		If Yes, please explain:									
	5.	Do you receive royalties	for patents	or other	intellectual property?	[	_Yes _No				
		If Yes, please explain:									
	6.	•	•	•	ible for intellectual property mana- titutional agreements, etc.?	•	_Yes				
			•								
	7.				ndling suspected research fraud?		 ]Yes				
	8.	If you are a research ins	-	-		•	_				
		a. How are you funded	d?								
	9.	Do you currently purcha				_	Yes □No				
		If Yes, please explain te	erms and lim	nits of insu	ırance:						

### F. CLINICAL TRIALS

(Please complete this section if you are or plan to conduct a clinical trial. If you do not, please skip this section.)

1. Please list your clinical trials, present and planned, for the next 12 months:

	DUCT NAME & OCOL NUMBER	# of New Subjects to be Enrolled Over the Next Policy Period		Clinical Trial Phase (I, II, III, or IV)	Countries Where the Trial Takes Place
Please	attach an IRB ap	proval, clinical trial pro	tocol and informed co	onsent document fo	r all clinical trials
schedu	led to occur ove	er the next 12 months.			
2.	How many clinica	al trials have you sponsor	red in the last 3 years?		
3.	What is the total	number of human subjec	ts enrolled in the last 3	years?	
4.		number of expanded acc months?	•		ts anticipated
5.	Have any of your	clinical trials been classi	ified as significant risk b	y the FDA or IRB?	□Yes □No
	If Yes, please pro	ovide details:			
	Have any of your of safety reasons	clinical trials been suspe ?	ended or discontinued ir	n whole, or in part, be	cause Yes No
	If Yes, please pro	ovide details:			
	What is the number in the last 5 years	oer of clinical trial "For Ca s?	ause Audits" conducted	by you or a regulator	y agency □Yes □No
	If Yes, please pro	ovide details:			
8.	Have any clinical	investigators been cited	for regulatory violations	3?	□Yes □No
	If Yes, please pro	ovide details:			
9.	Do you ever act a	as both trial sponsor and	clinical investigator?		☐Yes ☐No
	•	ovide details:			
10.		ride material or product for			□Yes □No
		ovide details:			
11.	Do you have form in place?	nalized Clinical Trial Susp	pension Standard Opera	ating Procedure (SOF	Ps) □Yes □No
		Clinical Investigators, CRC ces rendered (e.g., enrolli	·		arges □Yes □No
13.	What is the maxi	mum compensation you l	have offered trial partici	pants?	

### III. PRODUCTS COMPLETED OPERATIONS - REGULATORY AND RISK MANAGEMENT

## A. REGULATORY

	1.	Are you in compliance with Title 21 CFR Part 99 – Dissemination of Information on Unapproved/New Uses for Marked Drugs, Biologics and Devices?						
		If No, please prov	ide c	letails:				
	2.		•	duct(s) requiring the addit xisting label or instruction		•	cant	□Yes □No
		If Yes please prov	/ide d	details:				_
	3.	Do you have any	outst	anding FDA issues?				□Yes □No
		If Yes, please pro	Yes, please provide details:					
	4.		lave you been cited by any other regulatory agency (other than the FDA) for deficiencies and/or for noncompliance in the last 3 years?					
		If Yes, please pro	vide	details:				_
	5.	Do you have any	Oo you have any products approved for use by minors?					
В.	B. RISK MANAGEMENT							
	Qu	ality Control Assur	ance					
	1.	Do you have a for	rmal	risk management or qualit	ty ma	nagement program?		□Yes □No
	2.	Who is responsib Program?	le for	overseeing the Risk Man	agen	nent and Quality Assura	nce	
	3.	Do your quality co		procedures include forma	alized	l, standard operating pro	oced	ures for the following?
Fa	cility	sanitation controls		Written systems development methodology		Prototype development guidelines		Customer acceptance procedure
su		als and/or goods t to atmospheric es		In-process control point tests		Finished goods or batch testing		Batch records/serial product history record keeping
		r certification/ ation process		cGMP testing		Labeling and packaging		Written quality control program
ma		ng inspection of raw als or component		Alpha testing		Shelf like and/or calibration requirements		Product recall program
No	on-co	onforming material		Beta testing		Safe distribution of goods		Third Party Contract manufacturing
	4.	Do you audit your	risk	management programs a	nd st	andard operating proced	dures	?
	5.	Do you have any	steril	ized products?				□Yes □No
		If Yes:						
		a. Do you use a	third	party sterilizer?				□Yes □No
		b. Do you steriliz	ze th	e product on your premise	e?			□Yes □No
		If you responded	Yes	to either question above, p	oleas	e provide details:		
	6.	your products?		arty vendor to package, la				☐Yes ☐No
		ii i es, piease più	viue	uotalis				_

7.	Но	w I	ong	do y	ou	reta	ıin 1	testin	g an	d qua	alit	ty control	re	cord	s?								
8.	Are	e yo	ou ir	com	npli	anc	e v	vith al	ll app	olicab	le	cGMP, C	ЭC	P, G	LF	and QS g	uidel	line	es?			□Yes	□No
9.	Do	уо	u cc	mply	/ w	th a	any	of th	e foll	owin	g i	industry s	star	ndard	ds	? Please o	heck	ка	ll tha	t ap	ply:		
		7 T	ANS	<u></u>		$\overline{\Box}$	TE	DA		ПП	1	SO 13485		П	- F	REMS	ТП	Τ	Other	.			
	F	=+		Mark	ı	<u>⊔</u> П	+	SO 90	00		-	SO 14971	-			JL/CSA/EU	╁	+	Other	-+			
						<u> </u>	1							_	1		1 —	1					
		•		-		sup	ppl	iers?														∐Yes	∐No
				rketir	-																		
1.	Но	w c	lo y	ou se	ell y	our	pro	oduct	s an	d/or s	se	rvices? _											
2.	Describe the guarantees or warranties provided with your products or services?																						
3.		yo	u pr	ovide	e se	ervio	ce :	agree	men	ıts foı	· y	our produ	ucts	s?								□Yes	 □No
		' ′es	•					Ū			•	·										_	
	a. Do you audit your company's compliance with service agreements?																						
	b. Do you have a written preventative maintenance program for products under a																						
		se	ervic	e ag	ree	mer	nt?															□Yes	□No
4. Are any of your employees or subcontractors present during medical procedures?						□Yes	□No																
	If Y	es/	:																				
	a.		-	u ha otract			rm	al pol	licy p	rohib	iti	ng physic	cal	patie	ent	t contact by	/ an	em	ploy	ee		∐Yes	□No
	b.	D	о уо	u pro	ovic	le tr	rair	ning to	o you	ır em	pΙ	oyees an	d s	ubco	on	tractors req	gardi	ng	аррі	ropr	riate		
		CC	mmc	unic	atio	n a	ınd	cond	luct o	during	g r	nedical p	roc	edur	res	s?						□Yes	□No
5.	Do	yo	u ha	ave a	fo	mal	l ar	nd do	cum	entec	d t	raining pr	og	ram	foi	r sales pers	sonn	el?	)			□Yes	□No
6.		-					l ar	nd do	cum	entec	d t	raining pr	og	ram	foi	r installatio	n, se	rvi	ce a	nd			
_				ploye									_									∐Yes	_
7.		•						•		t, acti	nς	g Medical	Pr	otes	SIC	onals?						∐Yes	∐No
_			-					etails															
8.	em	plc	yee	s (or	su	bco	ntra	actors	s) re	ceivir				•		and post n						· —	
_		•				•		ıct lial	•													∐Yes	∐No
9.		•			_					•		abels and al basis?		arnın	ıgs	s, instructio	ns to	or u	ise, a	and		∐Yes	□No
10.	Do	уо	u ok	otain	wri	tten	ı CL	ıstom	er a	ccept	ar	nce at pre	-de	efine	d ı	milestones	or p	roj	ect s	tage	es?	∐Yes	□No
11.		-										r other sig			gre	eements fro	om a	ll c	usto	mei	rs	□Yes	□No
12.	•			-					•	•					рс	olicy and pr	oceo	dur	e?			_ □Yes	
		•										•				omers in th				ır pı	rodu		
	or services?																						
	If Y	⁄es	, ple	ase	pro	vide	e d	etails	:														

# Post Market Safety Surveillance and Complaint Handling How do you track your products? If batched produced, what is the average size? 2. What, if any, is the shelf-life expectancy of your product? \_ ☐Yes ☐No 3. Do you have a formal product recall program? If Yes: a. Do conduct test recalls? ☐Yes ☐No ☐Yes ☐No b. Do any of your products become part of another company's product? ☐Yes ☐No c. Are any of your products repackaged by any other companies? If Yes, please provide details: 4. Do you have a post implementation product or service evaluation or review procedure in place? ☐Yes ☐No 5. Do you have a formal policy for documenting and responding to customer complaints or requests for changes or repairs? ☐Yes ☐No If Yes: ☐Yes ☐No a. Who is responsible for fielding customer complaints? b. Do you have an escalation process in place to resolve customer complaints? ☐Yes ☐No c. Do you have a formal Corrective and Preventative Action Program (CAPA)? ☐Yes ☐No 6. Do you monitor and manage off label use of your products? ☐Yes ☐No 7. Please describe any actions you would take if you became aware of off label use of your products: In addition, would any of the following actions apply? Healthcare Professional / Dear Doctor Letter Additional studies

8.	Do you allow off label information dissemination?	□Yes □No
	If Yes, under what conditions:	

Expanded product monitoring

	Contract Risk Transfer     Do you have formal policied documentation?  Please check all that apply		d procedures in place	e to o	obtain	risk tran	esfer			Yes	□No
	CONTRACT RISK TRANSF	ER D	OCUMENTATION	Suppliers	Vendors	Contract MFG	Subs or Independent Contractors	Sterilizers	Distributors	OEMs	Customers
	Certificates of insurance issued an	nually	,								
	Additional Insured Status on Produ Liability Policy	ucts / (	Completed Operations								
	Hold Harmless language (in your fa	r mutually beneficial)									
	Indemnification language (in your f	favor o	or mutually beneficial)								
	Contract										
	Purchase Orders / Invoice (Incl. Te	erms 8	& Conditions)								
	Master Service Agreement										
	Distribution Agreement										
IV.	A. ERRORS AND OMISSIONS  (Please complete this section and Contract Information and Content of the Contract Information and Contract Information Informati	if you tract f	Risk Management ct, with your custome	ers, f	or you	r produc			·	Yes	□No
	TYPE OF CONTRACT		What Percent Standard/Non-D			Cus	at Perce stomized omer Rec	To M	eet		
	Formal Contract				%				%	_	
	Licensing Agreement				%				%	1	
	Purchase Order Other				%				<u>%</u> %	1	
	Do your standard contract     Check all that apply:	s, lice	ensing agreements o	r pur		orders	contain th	ne foll		orovisi	ons?
]	Statement of Work		Exclusive Remedy		Perfor	mance N	/lilestones	/Sched	dule of D	eliver	ables
	Limitation of Liability		Integration Clause		Custo	mer Maiı	ntenance	Provisi	on		
]	Limitation of Consequential Damages		Force Majeure		Hold I	larmless	/Indemnif	ication	Agreem	nent	
	Disclaimer of Warranties		Arbitration Clause		Condi	tions of c	customer a	accepta	ance of	produc	t or

service

3.	. Have your standard contracts, licensing agreements or purchase orders undergone legal review? ☐Yes ☐No							
	If No, please explain:							
4.	Are all deviations from you customer supplied contract		ensing agreements, purchase orders al counsel?	s or □Yes □No				
	If No, please give example	es of deviations that do r	not require legal review and sign-off:					
5.	Who can approve any variation in your standard contracts, licensing agreements or purchase orders provisions?							
6.	Do you ever negotiate contracts, licensing agreements or purchase orders with customers that include a provision for liquidated damages?							
	If Yes, please explain:							
7.	Do you ever negotiate standard contracts, licensing agreements or purchase orders with Customers in which you accept liability for consequential damages? ☐Yes ☐No							
	If Yes, please explain:							
8.	Do your sales and marketing personnel receive training regarding the acceptable provisions within your customer contracts, licensing agreements or purchase orders? ☐Yes ☐No							
9.	. Do you require subcontractors or independent contractors to carry Errors and Omissions insurance?  ☐Yes ☐No							
	If Yes, what is the minimur	n policy limit required?	\$					
10.	Do you notify customers of	f known problems with y	our products or services?	□Yes □No				
	If Yes, please describe:							
11.	Do you offer 24-hour produ	uct and service custome	er support?	☐Yes ☐No				
12.	Do you have a process to and suppliers?	evaluate the financial co	ondition of your customers	□Yes □No				
13.	What is your average cont	ract size and duration?						
14.	Describe your three larges	t customer contracts, po	urchase orders, licensing agreements	s or projects:				
CL	ISTOMER NAME	Product or Service Provided	Size of Contract, Purchase Order, Licensing Agreement or Project	Length of Contract				

### **B. INFORMATION SECURITY & PRIVACY AND PERSONAL INJURY**

(Please complete this section if you are applying for Information Security & Privacy and Personal Injury coverage.)

Organization - Cybersecurity

1. Indicate the type and number of unique records collected/maintained by you or others on your behalf. Check all that apply:

1 1	PE OF INFORMATION	Number of Records									
Biometric	information		<50K		50K-500K		500K-1M		1M-3M		>3M
Financial	account numbers		<50K		50K-500K		500K-1M		1M-3M		>3M
	sonally identifying information al security numbers, passport		<50K		50K-500K		500K-1M		1M-3M		>3M
Protected	Health Information		<50K		50K-500K		500K-1M		1M-3M		>3M
Credit card numbers			<50K		50K-500K		500K-1M		1M-3M		>3M
	ormation not described above e, address, telephone numbers, etc.		<50K		50K-500K		500K-1M		1M-3M		>3M
2.	You have (check all that apply):										
a.	A regularly tested and update	d Wri	itten Info	rmati	on Security	Plan					
b.	A regularly tested and update	d Wri	itten Inci	dent	Response P	lan					
	Are the WISP and/or the IRP	teste	d at leas	t ann	ually?			□Y	′es □No		
c. A designated Chief Information Security Officer (or equivalent)?											
Back-ups – You make ( <u>select one</u> ):      Regular, full and incremental backups of critical data and computer systems											
b.	Occasional and full back-ups					ysten	ns		L		
C.	No back-ups of critical data ar		•						L		
-	either 2.a. or 2.b. has been selec										
-	either 2.a. or 2.b. has been selec			• •					′es □No		
IT 6	either 2.a. or 2.b. has been selec						•		00 h		
	Within 24 hours Within 25-4	8 noi	urs 🔲 v	vitnin	149-130 nou	ırs _	Greater th	nan 1	30 nours		
	Are devices connected to your r			•	• • •		· ·	sis?		es [	□No
5.	Are local administration rights di (i.e., laptops/desktops)?	sable	ed for reg	gular	employees	on th	eir devices			es [	□No
6.	Is Multifactor Authentication (MF All administration accounts?	A) de			enforced on: ccess?	_	l email acco	ounts	?		
7.	Have legacy email protocols (su	ch as	s IMAP,	POP	3, and SMTF	P) be	en disabled	?		es [	□No
	Is there any end of life (EOL) or (EOL/EOS software is where de			•	•	-		k?		es [	□No
	If Yes, is it segregated?	,	,	•	<u> </u>		. ,			es [	No
8.	Do you have an internal Security	v One	erations	Cent	er (SOC) or	utilize	e a third par	rtv fo			_
<b>.</b>	or Managed Detection and Resp							.,		es [	□No

	res, indicate internal or the name of the service provider:	
ı	Provider: 🗌 24x7 Provider 🗌 Working hours onl	y provide
	How often are network penetration tests conducted on your network (tests can be perform a third party on your behalf)?	ed by yo
] N	lever/Occasionally 🗌 Annually 🔲 Semi-annually 🔲 Quarterly 🔲 Monthly or more often	n
0. l	Patching and Updates – You have (select one):	
a.	Automatic updates enabled with patch management verification procedure	
b.	Automatic updates enabled	
c.	Manual updates	
1.	Firewalls – You have (select one):	
a.	Hardware and software firewalls deployed	
b.	Hardware firewall deployed	
c.	No firewalls deployed	
2.	Endpoint Detections & Response (EDR) and Intrusion Detection Software – You have (see	lect one):
a.	EDR and Intrusion detection software installed or activated on all Computer Systems	
b.	EDR solution installed or activated on all endpoints	
c.	No EDR solution or intrusion detection software installed or activated	
	Network Security – When working remotely, your employees (select one):	
a.	Access a segmented network via Virtual Private Network  Access the network via Virtual Private Network	+
b.		+
C.	Do not access a Virtual Private Network	
4.	Email Security – You have (select one):	
a.	Web and email (DKIM, DMARC, SPF) filtering enabled	
b.	Web or email (DKIM, DMARC, SPF) filtering enabled	
c.	Neither Web nor email filtering enabled	
5.	Encryption – Your encryption is (select one):	
a.	Deployed for Data at rest, in transit and on mobile devices	
b.	Deployed for Data at rest	
c.	Not deployed – Please Explain:	
	Accountability – When accessing computer systems & information, employees and third passued (select one):	arties
a.	Separate and unique accounts with strong passwords (i.e., NIST, MS, etc.). Access is restricted to that needed to perform their duties (i.e., separate administration accounts)	
b.	Separate and unique accounts with strong passwords (i.e., NIST, MS, etc.)	
C.	Separate and unique accounts with no password construction requirements	

	k	personal information (select one):				
Ī	a.	Formal and documented annual employee training program				
	b.	Formal but undocumented employee training program				
Ī	c.	No employee training program				
-	TCP 19. F	Has traffic using Remote Desktop Protocol (RDP) TCP ports 3389 and Serve ports 445, 139, and 149 been blocked?  Please provide the name of the product and/or service deployed for the follow gories:	□Yes □No			
	S	SECURITY SOLUTIONS Provider/Produc	t			
		rotection Platform (EPP)				
•		Isolation and Containment				
		etection and Response (EDR)				
		etection and Response (NDR)				
Security (SIEM)	y Info	ormation and Event Management				
_		Access Management (PAM) /				
Identify	& A	ccess Management (IAM)				
2	<b>a</b>	Do use vendors for any of the following:  a. Customer Service?  b. Webhosting/data center operations?	∐Yes ∐No ∐Yes ∐No			
		c. Data Processing?	□Yes □No			
2 Prod	d. Other – Please describe:  21. If user information is collected on your website, do users have the option to opt in or opt out of the allowing the collections or use of their information?  22. Does your company adhere to the requirements and guidance set forth with FDA and any other regulatory standards to assure cybersecurity exposures are adequately controlled in the design, productions and post-production of any medical devices manufactured or distributed by your company?  Product or Service Cybersecurity  1. Do you have a comprehensive cybersecurity plan in place which identifies the vulnerabilities and/or threat sources which may permit the unauthorized access, modification, misuse, or denial of use; or the unauthorized use of information that is stored, accessed or transferred					
		from your product or service to an external recipient and may impact patient s	safety?			
		If Yes, does it include?				
г	(	(Check all that apply)				
		Monitoring cybersecurity information sources for emerging vulnerabilities a	and risk			
		Protocols for vulnerability intake and handling				
		Defined process to detect and assess both the presence and impact of a	ulnerability or threat			
		Defined acceptable performance with respect to protecting, responding, a cybersecurity risk	nd recovering from a			
		A vulnerability disclosure policy and practice				

17. Information Security Training – You have the following employee training program to safeguard

Deploying mitigations that address cybersecurity risk early and prior to exploitation

	(Ct	neck all that apply)				
		Defined process for assessing the exploitability of a cybersecurity vulnerability				
		Defined process to evaluate cybersecurity risk versus essential clinical performance o or service	f your produc			
		Defined process to determine whether or not the exploitation of an identified vulnerabic categorized as an acceptable or unacceptable risk	lity can be			
		Defined process to communicate threats				
		Defined process for assessing the severity impact to patient health of a cybersecurity	vulnerability			
		Defined requirements necessary to achieve device safety and effectiveness				
		Defined process to systematically conduct risk evaluations and determine whether a culture vulnerability affecting your product or service presents an acceptable or unacceptable				
		Protocols to establish, document, and maintain throughout the lifecycle of the product ongoing process for identifying hazards associated with cybersecurity	or service, ar			
		you incorporate the following into your product or services' cybersecurity remediation neck all that apply)	protocols?			
		Ensure the version for acquired software is supported by the vendor				
		Protect web applications by deploying Web Application Firewalls (WAF) and non web-applications with specific application firewalls	based			
		Ensure explicit error checking is performed and documented for all input on in-house developed software				
		Test in-house developed and third party procured web applications for common security weaknesses prior to deployment and whenever updates are made				
		Maintain separate environments for production and nonproduction systems				
	Use standard hardening configuration templates for applications that rely on a database					
		Ensure software development personnel receive training in writing secure code for the development environment	eir specific			
		Ensure development artifacts are not included in deployed software or accessible in p environment for in-house developed applications	roduction			
4.	Ha	ve you had to remediate cyber security vulnerabilities in the past 3 years?	□Yes □No			
	If Y	es, were they successful?	☐Yes ☐No			
Pers	son	al Injury Liability				
		you sell or share personal and/or confidential information gathered from customers or ers? (This includes information gathered form your website or by other means.)	□Yes □No			
		es, do you notify and obtain the consent of customers or others prior to disseminating information?	□Yes □No			
2.	Do	you have a chat room, bulletin board or social media site?	□Yes □No			
	If Y	'es, please provide the following information:				
	a.	Who are the primary users of the chat room, bulletin board or social media site (i.e., evendors, customers, etc.)?	employees,			
	b.	Do you monitor the chat room, bulletin board or social media site?	Yes □No			
	C.	How quickly do you remove content and posts when you are notified they are unacce infringing?	ptable or			

2. Do you incorporate the following into your product or service Risk Management protocols?

#### C. MEDIA AND CONTENT

(Please complete this section if you are applying for Media and Content coverage.) Intellectual Property 1. Do you provide any of the following? (Check all that apply) Applications/software that enables the copying or dissemination of the content of others (ie., music, art, photos, graphics, video, written works, etc.) A file swapping network Access to the file sharing activities (i.e., peer to peer) □Yes □No 2. Do you have intellectual property or business methods clearance procedures? If Yes, check all that apply: The acquisition of all the necessary rights, licenses, releases and consents applicable to content or services Legal review of all referral and affiliate program agreements created or provided by you or third parties Legal review of the following performed prior to release, use. dissemination of or modification to regardless of the medium Permission to use and legal review of the trademarks П (check all that apply): and/or service marks of others ☐ Content ☐ Business Methods ☐ Product Technology used ☐ Websites ☐ Work Services ☐ Advertising and Marketing New hire and independent contractor agreements Trademark and/or service mark searches and clearances for all your: include signed statements that new employees and П contractors will not disseminate or use any previous ☐ Domain names employer's or client's trade secrets or other intellectual Service names, designs or logos property Content searches and clearances perform by your: The contractual acquisition of all rights (including (check all apply) electronic rights) to work done by you by third parties, including hold harmless and indemnification clauses, ☐ Professional search ☐ Computerized ☐ Legal counsel which inure to your benefit pertaining to that work company database search Legal review performed with respect to laws in Permission from owners of sites you link or frame jurisdictions outside the U.S.

#### V. DECLARATION AND SIGNATURE

available or disseminated

Disclaimers on your website pertaining to content made

The undersigned, acting on behalf of all Applicants, declare that the statements set forth in this Application are true and correct and that thorough efforts were made to obtain requested information from each and every Applicant proposed for this insurance to facilitate the proper and accurate completion of this Application.

The undersigned agree that the information provided in this Application and any material submitted herewith are the representations of all the Applicants and are the basis for issuance of the insurance policy provided by us. Any material submitted with the Application shall be maintained on file (either electronically or paper) with us.

It is further agreed that:

- If any of the Applicants discover or become aware of any significant change in the condition of the Applicant Organization between the date of this Application and the policy inception date, which would render the Application inaccurate or incomplete, notice of such change will be reported in writing immediately;
- Any policy issued, will be in reliance upon the truthfulness of the information provided in this Application; provided, however, with respect to such information, no knowledge or information possessed by any Applicant shall be imputed to any other Applicants. If any person or persons knew as of the policy inception

Legal review of all licensing and/or cross-licensing agreements

- date that such information contained in the Application(s) were untrue, inaccurate or incomplete, then coverage may be denied or canceled if such information was material to issuance of the policy;
- Statements in the Application, facts pertaining to or knowledge possessed by the individual signing the Application shall be imputed to the Applicant; and
- The signing of this Application does not bind the undersigned to purchase insurance.

**GENERAL FRAUD NOTICE:** Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or knowingly provides false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

#### ATTENTION APPLICANTS IN THE FOLLOWING JURISDICTIONS

ALABAMA, ARKANSAS, DISTRICT OF COLUMBIA, LOUISIANA, MARYLAND, NEW MEXICO, RHODE ISLAND AND WEST VIRGINIA: Any person who knowingly (or willfully in MD) presents a false or fraudulent claim for payment of a loss or benefit or knowingly (or willfully in MD) presents false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

**CALIFORNIA:** For your protection, California law requires the following to appear on this form. Any person who knowingly presents false or fraudulent information to obtain or amend insurance coverage or to make a claim for payment of a loss is guilty of a crime and may be subject to fines and confinement in state prison.

**COLORADO:** It is unlawful to knowingly provide false, incomplete, or misleading facts or information to an insurance company for the purpose of defrauding or attempting to defraud the company. Penalties may include imprisonment, fines, denial of insurance and civil damages. Any insurance company or agent of an insurance company who knowingly provides false, incomplete, or misleading facts or information to a policyholder or claimant for the purpose of defrauding or attempting to defraud the policyholder or claimant with regard to a settlement or award payable from insurance proceeds shall be reported to the Colorado Division of Insurance within the Department of Regulatory Agencies.

**FLORIDA AND OKLAHOMA:** Any person who knowingly and with intent to injure, defraud or deceive any insurer files a statement of claim or an application containing any false, incomplete, or misleading information is guilty of a felony (of the third degree in FL).

KANSAS: Any person who, knowingly and with intent to defraud, presents, causes to be presented or prepares with knowledge or belief that it will be presented to or by an insurer, purported insurer, broker or any agent thereof, any written, electronic, electronic impulse, facsimile, magnetic, oral, or telephonic communication or statement as part of, or in support of, an application for the issuance of, or the rating of an insurance policy for personal or commercial insurance, or a claim for payment or other benefit pursuant to an insurance policy for commercial or personal insurance which such person knows to contain materially false information concerning any fact material thereto; or conceals, for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act.

**KENTUCKY**, **OHIO AND PENNSYLVANIA**: Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information or conceals for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

MAINE, TENNESSEE, VIRGINIA, AND WASHINGTON: It is a crime to knowingly provide false, incomplete or misleading information to an insurance company for the purpose of defrauding the company. Penalties (may)\* include imprisonment, fines and denial of insurance benefits. \*Applies in ME Only.

**NEW HAMPSHIRE AND NEW JERSEY:** Any person who includes any false or misleading information to the best of her/his knowledge on an application for an insurance policy is subject to criminal and civil penalties.

**OREGON:** Any person who knowingly and with intent to defraud or solicit another to defraud the insurer by submitting an application containing a false statement as to any material fact may be violating state law.

**PUERTO RICO:** Any person who knowingly and with the intention of defrauding presents false information in an insurance application, or presents, helps, or causes the presentation of a fraudulent claim for the payment of a loss or any other benefit, or presents more than one claim for the same damage or loss, shall incur a felony and, upon conviction, shall be sanctioned for each violation by a fine of not less than five thousand dollars (\$5,000) and not more than ten thousand dollars (\$10,000), or a fixed term of imprisonment for three (3) years, or both penalties. Should aggravating circumstances [be] present, the penalty thus established may be increased to a maximum of five (5) years, if extenuating circumstances are present, it may be reduced to a minimum of two (2) years.

**VERMONT FRAUD NOTICE:** Any person who knowingly presents a false statement in an application for insurance may be guilty of a criminal offense and subject to penalties under state law.

**NEW YORK:** Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information or conceals for the purpose of misleading information concerning any fact material thereto commits a fraudulent insurance act, which is a crime and subjects such person to civil penalties not to exceed five thousand dollars and the stated value of the claim for each such violation.

This Application must be signed by a representative of the Applicant acting as the authorized representative of the person(s) and entity(ies) proposed for this insurance.

DATE:	SIGNATURE/TITLE
	(Chief Executive Officer, President, Chief Financial Officer, Managing Partner or Owner)
Produced By: Agent: Agent Signature:	Agency:
Agency Taxpayer ID or SS No.: Address (Street, City, State, Zip):_	Agent License Number: